CLBS News and Press, Caladrius Biosciences Inc. From 05/19/22

Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two patients dosed Top-line data from all subjects expected by the first quarter of 2023 BASKING RIDGE, N.J., May 19, 2...

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse dise...

The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Caladrius Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation

Caladrius Biosciences, Inc. (CLBS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kr...

Caladrius Biosciences press release (NASDAQ:CLBS): Q1 GAAP EPS of -$0.07. Shares +2%. As of March 31, 2022, the Company had cash, cash equivalents and marketable securities of approximately $88.5 million For further details see: Caladrius Biosciences GAAP EPS of -$0.07

Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development portfolio Conference call begins today at 4:30 p.m. Eastern time BASK...

NEW YORK, NY / ACCESSWIRE / April 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Campus Communities, Inc. (...

BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse di...

Penny stocks have a remarkable reputation for ridiculous gains. While these moves can come swiftly, retail traders tend to flock to the cheap stocks for their opportunity to capitalize on such an opportunity. Any given day, we see at least a few penny stocks surging hundreds of perc...

The shares of clinical-stage biotech Caladrius Biosciences (NASDAQ:CLBS) have added ~29% in the pre-market Wednesday in reaction to a merger agreement with the privately held Cend Therapeutics. Per the terms, Cend will merge with a subsidiary of Caladrius (CLBS) in an all-stock deal...